NeuExcell Therapeutics names Lori Gavrin as Chief Business and Strategy Officer
STATE COLLEGE, Penn., Oct. 18, 2021 -- (Healthcare Sales & Marketing Network) -- NeuExcell Therapeutics Inc. (www.neuexcell.com) today announced the appointment of Lori Gavrin, Ph.D. to the new position of Chief Business and Strategy Officer, effective im... Biopharmaceuticals, Personnel NeuExcell Therapeutics, gene therapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 18, 2021 Category: Pharmaceuticals Source Type: news

A decade after gene therapy, children born with deadly immune disorder remain healthy
Over a decade ago, UCLA physician-scientists began using a pioneering gene therapy they developed to treat children born with a rare and deadly immune system disorder.They now report that the effects of the therapy appear to be long-lasting, with 90% of patients who received the treatment eight to 11 years ago still disease-free.ADA-SCID, oradenosine deaminase –deficient severe combined immunodeficiency, is caused by mutations in the gene that creates the ADA enzyme, which is essential to a functioning immune system. For babies with the disease, exposure to everyday germs can be fatal, and if untreated, most will die...
Source: UCLA Newsroom: Health Sciences - October 15, 2021 Category: Universities & Medical Training Source Type: news

VectorBuilder and Landau enter into strategic partnership to establish world & rsquo;s first primate gene therapy R & amp;D center
(Source: The Scientist)
Source: The Scientist - October 15, 2021 Category: Science Tags: The Scientist The Marketplace Source Type: news

The Petri Dish: Gene therapy startup launches, Charles River Labs sells two sites
While some in the life sciences industry create drugs and devices to tackle the Covid-19 pandemic, their colleagues are busy as ever raising money, testing new drugs, expanding facilities and more. Here's The Petri Dish, a roundup of news that may get overlooked amid the influx of Greater Boston life sciences and health care happenings. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - October 14, 2021 Category: Pharmaceuticals Authors: Rowan Walrath Source Type: news

Southwest Airlines "sickout" protest spreads to Amtrak, which is canceling trains due to employees refusing covid "vaccination"
(Natural News) After announcing that nearly all of its 18,000 employees will need to be “fully vaccinated” for the Wuhan coronavirus (Covid-19) by November 22, Amtrak incurred a “sickout” much like the one that Southwest Airlines currently faces. Amtrak employees who do not want to permanently alter their DNA with experimental gene therapy walked off... (Source: NaturalNews.com)
Source: NaturalNews.com - October 13, 2021 Category: Consumer Health News Source Type: news

Genetic kidney disorder reversible in preclinical models, Yale study finds
Using gene therapy in mice, Yale researchers were able to reverse the damage caused by ADPKD, an inherited disease that causes cysts to develop in kidneys. (Source: Yale Science and Health News)
Source: Yale Science and Health News - October 12, 2021 Category: Universities & Medical Training Source Type: news

Spark signs gene therapy licensing deal valued at up to $328.5M
Philadelphia gene therapy pioneer Spark Therapeutics signed a collaboration and licensing agreement Tuesday that gives its exclusive rights to further develop and commercialize a Swedish company's experimental focal epilepsy treatment. Under the terms of agreement, Spark, of division of Roche, will pay CombiGene up to $328.5 million plus royalties for the rights to its CG01 gene therapy project. The deal includes $8.5 million upfront and $50 million when certain preclinical and clinical milestones… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - October 12, 2021 Category: Pharmaceuticals Authors: John George Source Type: news

Spark signs gene therapy licensing deal valued at up to $328.5M
Philadelphia gene therapy pioneer Spark Therapeutics signed a collaboration and licensing agreement Tuesday that gives its exclusive rights to further develop and commercialize a Swedish company's experimental focal epilepsy treatment. Under the terms of agreement, Spark, of division of Roche, will pay CombiGene up to $328.5 million plus royalties for the rights to its CG01 gene therapy project. The deal includes $8.5 million upfront and $50 million when certain preclinical and clinical milestones… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 12, 2021 Category: Biotechnology Authors: John George Source Type: news

Lab Notes: A Pennovation Lab lease deal, an Proscia AI advancement, a cell therapy collaboration and more
This week's Lab Notes includes a growing cell and gene therapy company finding a new home, an advance in the use of artificial intelligence to diagnose cancer and a collaboration agreement. Here's the roundup: Interius BioTherapeutics The cell and gene therapy company spun out of the University of Pennsylvania has signed a lease deal to occupy about 17,700 square feet at Pennovation Lab in the Greys Ferry section of Philadelphia. Interius was co-founded in 2019 by Dr. Saar Gill, a Penn Medicine… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - October 8, 2021 Category: Health Management Authors: John George Source Type: news

Lab Notes: A Pennovation Lab lease deal, an Proscia AI advancement, a cell therapy collaboration and more
This week's Lab Notes includes a growing cell and gene therapy company finding a new home, an advance in the use of artificial intelligence to diagnose cancer and a collaboration agreement. Here's the roundup: Interius BioTherapeutics The cell and gene therapy company spun out of the University of Pennsylvania has signed a lease deal to occupy about 17,700 square feet at Pennovation Lab in the Greys Ferry section of Philadelphia. Interius was co-founded in 2019 by Dr. Saar Gill, a Penn Medicine… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 8, 2021 Category: Biotechnology Authors: John George Source Type: news

The Petri Dish: Takeda taps Selecta for gene therapy, BICO makes another buy
While some in the life sciences industry create drugs and devices to tackle the Covid-19 pandemic, their colleagues are busy as ever raising money, testing new drugs, expanding facilities and more. Here's The Petri Dish, a roundup of news that may get overlooked amid the influx of Greater Boston life sciences and health care happenings. BICO makes another acquisition Just over a month after restructuring, Boston-based BICO — short for "bioconvergence" — has acquired another company, this time… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - October 6, 2021 Category: American Health Authors: Rowan Walrath Source Type: news

The Petri Dish: Takeda taps Selecta for gene therapy, BICO makes another buy
While some in the life sciences industry create drugs and devices to tackle the Covid-19 pandemic, their colleagues are busy as ever raising money, testing new drugs, expanding facilities and more. Here's The Petri Dish, a roundup of news that may get overlooked amid the influx of Greater Boston life sciences and health care happenings. BICO makes another acquisition Just over a month after restructuring, Boston-based BICO — short for "bioconvergence" — has acquired another company, this time… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 6, 2021 Category: Biotechnology Authors: Rowan Walrath Source Type: news

Voyager Therapeutics stock soars on Pfizer deal
Shares of Cambridge biotech Voyager Therapeutics Inc. rose more than 60% on the news that the company inked a $630 million licensing deal with Pfizer Inc. Pfizer (NYSE: PFE) is paying Voyager (Nasdaq: VYGR) $30 million up front, plus another $600 million in potential milestone payments, to use the company's specially engineered capsids for its growing gene therapy programs. Capsids, geometric-looking "heads" on viruses, are where viral genetic mater ial is stored; altering them could make for more… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - October 6, 2021 Category: Pharmaceuticals Authors: Rowan Walrath Source Type: news

Gene therapy firm expands operations in RTP as headcount reaches 100
A gene therapy developer based in Research Triangle Park has expanded its operations as it prepares to move its programs into clinical trials. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - October 5, 2021 Category: Pharmaceuticals Authors: Zac Ezzone Source Type: news

Gene therapy firm expands operations in RTP as headcount reaches 100
A gene therapy developer based in Research Triangle Park has expanded its operations as it prepares to move its programs into clinical trials. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 5, 2021 Category: Biotechnology Authors: Zac Ezzone Source Type: news

The vaccine death report
(Natural News) The purpose of this report is to document how all over the world millions of people have died, and hundreds of millions of serious adverse events have occurred, after injections with the experimental mRNA gene therapy. (Article by Dr David John Sorenson & Dr Vladimir Zelenko MD republished from Principia-Scientific.com) We also reveal... (Source: NaturalNews.com)
Source: NaturalNews.com - October 4, 2021 Category: Consumer Health News Source Type: news

Improving Therapeutic Success: Focus on Cell and Gene Therapy
Researchers combine immune profiling with single cell sequencing to enhance immunotherapies. (Source: The Scientist)
Source: The Scientist - October 1, 2021 Category: Science Tags: The Marketplace Source Type: news

Defining the terms: An entry-level guide to the world of cell and gene therapies
Here is a basic overview of one of the most exciting fields in biotech (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - October 1, 2021 Category: Pharmaceuticals Authors: Kevin Truong Source Type: news

What's in the pipeline for emerging Bay Area cell and gene therapy startups?
According to a March 30 report from the Alliance for Regenerative Medicine, nearly $20 billion of investment flowed into biotech companies developing cell-, gene- and tissue-based therapies last year, more than double the figure from the previous year. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - October 1, 2021 Category: Pharmaceuticals Authors: Ahalya Srikant Source Type: news

How much should it cost to save a life? Gene and cell therapies raise new questions about price versus value
Cell and gene therapies hold tremendous promise at tremendous prices, which leads to the question: How much is a cure worth if it ’s unaffordable? (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - October 1, 2021 Category: Pharmaceuticals Authors: Alisha Green Source Type: news

Castle Creek to collaborate with Mayo Clinic on developing new gene therapies for rare diseases
Castle Creek Biosciences Inc. is teaming up with the Mayo Clinic to advance the development of potential gene therapies for two rare genetic connective tissue disorders. "We expect this initiative will be the first of multiple Castle Creek strategic collaborations with leading medical research institutions that have the potential to expand our innovative gene therapy discoveries for rare diseases," said Matthew Gantz, CEO of Castle Creek Biosciences. The partners hip will focus on the discovery… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 30, 2021 Category: Pharmaceuticals Authors: John George Source Type: news

Amicus Therapeutics spins off genetic medicine unit in $600M SPAC deal
Amicus Therapeutics Inc., a life sciences company which at the start of this year moved it headquarters from New Jersey to Philadelphia, unveiled plans Wednesday to spinoff a "next-generation genetic medicine company" in a deal valued at $600 million. The company, Caritas Therapeutics, is being created through a merger of part of the gene therapy business of Amicus (NASDAQ: FOLD) with ARYA Sciences Acquisition Corp. IV, a special purpose acquisition company, or SPAC, sponsored by Perceptive Advisors.… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - September 29, 2021 Category: American Health Authors: John George Source Type: news

Gene therapy manufacturer Andelyn adds lab in Dublin as construction continues in OSU Innovation District
Andelyn Biosciences Inc. is adding a second laboratory in Dublin, and will move into its headquarters in Ohio State University's Innovation District before construction is complete. Not quite two years old, the gene therapy manufacturing spinoff of Nationwide Children's Hospital has grown to 185 jobs – and is outgrowing temporary space spread across three separate hospital buildings. "We've got a full list of client projects we needed to serve; that’s why we decided to e xpand," CEO Mayo Pujols… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - September 29, 2021 Category: American Health Authors: Carrie Ghose Source Type: news

Roche presents new data at World Muscle Society (WMS) 2021 highlighting new advances for people living with rare neuromuscular disorders
Basel, 24 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced data from across its growing neuromuscular portfolio at the World Muscle Society (WMS) Virtual Congress 20 – 24 September 2021. The presentations included additional results from the RAINBOWFISH study, evaluating the efficacy and safety of Evrysdi® (risdiplam) in babies with pre-symptomatic spinal muscular atrophy (SMA) from birth to six weeks of age and data supporting the continued clinical investig ation of gene therapy, SRP-9001, in Duchenne muscular dystrophy (DMD).“These new data for Evrysdi may help extend the potential ben...
Source: Roche Media News - September 24, 2021 Category: Pharmaceuticals Source Type: news

Roche presents new data at World Muscle Society (WMS) 2021 highlighting new advances for people living with rare neuromuscular disorders
Basel, 24 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced data from across its growing neuromuscular portfolio at the World Muscle Society (WMS) Virtual Congress 20 – 24 September 2021. The presentations included additional results from the RAINBOWFISH study, evaluating the efficacy and safety of Evrysdi® (risdiplam) in babies with pre-symptomatic spinal muscular atrophy (SMA) from birth to six weeks of age and data supporting the continued clinical investig ation of gene therapy, SRP-9001, in Duchenne muscular dystrophy (DMD).“These new data for Evrysdi may help extend the potential ben...
Source: Roche Investor Update - September 24, 2021 Category: Pharmaceuticals Source Type: news

Streamlining Cell and Gene Therapy Research
The right tools solve researchers ’ challenges and advance therapy development. (Source: The Scientist)
Source: The Scientist - September 23, 2021 Category: Science Tags: The Marketplace Source Type: news

American Gene Technologies HIV Cure Clinical Trial Shows Additional...
DSMB unanimously approves continuation of Phase 1 trial, advancing AGT closer to establishing safety of HIV gene therapy.(PRWeb September 23, 2021)Read the full story at https://www.prweb.com/releases/american_gene_technologies_hiv_cure_clinical_trial_shows_additional_progress_with_no_serious_adverse_events_saes/prweb18211605.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 23, 2021 Category: Pharmaceuticals Source Type: news

Penn gene therapy spinout taking on rare retinal diseases launches with $19M in seed funding
A new gene therapy company attempting to commercialize the research of Penn Medicine's Dr. Jean Bennett launched Wednesday in North Carolina with $19 million in seed capital. The company, Opus Genetics, is the first spinout company internally conceived and launched by the Retinal Degeneration Fund (RD Fund), the venture arm of the Foundation Fighting Blindness. The fund was created to further the foundation's mission of backing research to prevent, treat and cure retin al degenerative diseases. Opus… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - September 22, 2021 Category: American Health Authors: John George Source Type: news

Novartis acquires Arctos Medical, expanding optogenetics portfolio to bring gene therapies to patients with severe vision loss
Novartis announced that it has acquired Arctos Medical, adding a pre-clinical optogenetics-based AAV gene therapy program and Arctos’ proprietary technology to its ophthalmology portfolio. The acquisition underscores the Novartis commitment to finding treatments for patients with vision loss and the potential of optogenetics as the basis of successful therapeutics. (Source: World Pharma News)
Source: World Pharma News - September 22, 2021 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Gene Therapy Research Accelerates for Retinal Diseases Gene Therapy Research Accelerates for Retinal Diseases
Patients who have rare retinal diseases — as well as those with more common ones — may benefit from a surge in gene therapy research.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 17, 2021 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Catalent Signs Commercial Supply Agreement with Phathom...
Catalent, the leading global provider of development sciences and manufacturing platforms for medicines, including biotherapeutics; cell and gene therapies; and consumer health products, today...(PRWeb September 16, 2021)Read the full story at https://www.prweb.com/releases/catalent_signs_commercial_supply_agreement_with_phathom_pharmaceuticals/prweb18200429.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 16, 2021 Category: Pharmaceuticals Source Type: news

Pioneering Gene Therapy Freed Her of Sickle Cell. Is a Cure at Hand?
Such treatments are extraordinarily promising and costly. Will the Biden administration commit to spending that could speed clinical trial results? (Source: NYT Health)
Source: NYT Health - September 14, 2021 Category: Consumer Health News Authors: Gina Kolata Tags: Sickle Cell Anemia Drugs (Pharmaceuticals) Research Clinical Trials Genetic Engineering Genetics and Heredity Race and Ethnicity Source Type: news

S12 nonclinical biodistribution considerations for gene therapy products
ICH - Safety (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - September 13, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

AbbVie and REGENXBIO Announce Eye Care Collaboration
AbbVie and REGENXBIO form a strategic partnership combining eye care and gene therapy expertise Companies will develop and commercialize RGX-314, an investigational gene therapy for wet age-related macular degeneration, diabetic retinopathy and other ch... Biopharmaceuticals, Regenerative Medicine, Ophthalmology AbbVie, REGENXBIO, gene therapy, macular degeneration, diabetic retinopathy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 13, 2021 Category: Pharmaceuticals Source Type: news

SICK AND TWISTED: Jimmy Kimmel wants all unvaccinated people to DIE, but hopes the Covid clot shot won't clog his son's blood and strain his heart that already has an oxygen-depriving birth defect
(Natural News) Have you heard of the new comedy show based on children dying? Yes, it’s hosted by Jimmy Kimmel, who’s running a “hit piece” on how hospitals should deny all care to anyone who won’t take the China Flu gene therapy jabs. Send them home to die, is the message, the punch line. Tell... (Source: NaturalNews.com)
Source: NaturalNews.com - September 12, 2021 Category: Consumer Health News Source Type: news

International gene therapy developer Exegenesis opens U.S. offices in Montco, plans to triple local staff
The company has 10 employees in the Philadelphia region, and expects to add another 25 over the next year. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 10, 2021 Category: Pharmaceuticals Authors: John George Source Type: news

Penn spinout led by veteran pharma execs emerges from stealth mode, raises $50M to advance gene-editing technology
The company's technology is the culmination of more than 30 years of gene therapy and editing experience developed in the laboratory of Dr. Jim Wilson. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 9, 2021 Category: Biotechnology Authors: John George Source Type: news

Mammoth Biosciences Raises $195 Million, Vaulting Its Crispr Tech To Unicorn Status
Investors are betting the protein toolbox of the four-year-old startup can solve one of gene therapy ’s trickiest problems: getting treatments into the patient’s body. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - September 9, 2021 Category: Pharmaceuticals Authors: Katie Jennings, Forbes Staff Tags: Healthcare /healthcare Innovation /innovation Science /science Venture Capital /venture-capital Editors' Pick editors-pick Coronavirus Source Type: news

Obsidian Therapeutics eyes IPO after $115M fundraise
After raising $115 million from a handful of high-profile investors, cell and gene therapy startup Obsidian Therapeutics has its sights set on an IPO by early 2023. The company expects to advance its first cancer drug into the clinic in the same timeframe. It also plans to move to Bedford. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - September 9, 2021 Category: Health Management Authors: Rowan Walrath Source Type: news

This Startup Just Raised $50 Million To Deliver Gene Therapies For Rare Diseases
iECURE aims to use gene editing to treat patients suffering from rare genetic disorders. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - September 9, 2021 Category: Pharmaceuticals Authors: Aayushi Pratap, Forbes Staff Tags: Healthcare /healthcare Innovation /innovation Editors' Pick editors-pick Source Type: news

Spark Therapeutics enters into gene therapy collaboration targeting Huntington's disease
The agreement includes upfront, research and development, and sales milestone payments and license fees valued at up to about $190 million. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 7, 2021 Category: Biotechnology Authors: John George Source Type: news

U.S. FDA Placed a Clinical Hold on BMN 307 Phearless Phase 1/2 Gene Therapy Study in Adults with PKU Based on Interim Pre-clinical Study Findings
BioMarin Also Pausing Further Enrollment of Additional Participants Outside the U.S. in Phearless Phase 1/2 Study BioMarin is Working with FDA and Other Health Authorities and Will Communicate Next Steps When Available SAN RAFAEL, Calif., Sept. 6, 20... Biopharmaceuticals, FDA BioMarin Pharmaceutical, phenylalanine hydroxylase, phenylketonuria (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 6, 2021 Category: Pharmaceuticals Source Type: news

NeuExcell Therapeutics Raises $10+ Million Series Pre-A Round To Continue Its Company Growth
STATE COLLEGE, Pa., Aug. 30, 2021 -- (Healthcare Sales & Marketing Network) -- NeuExcell Therapeutics (www.neuexcell.com), a gene therapy company focusing on neurodegenerative diseases, has announced a $10+ million Series Pre-A financing round. The round ... Regenerative Medicine, Neurology, Venture Capital NeuExcell Therapeutics, gene therapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 30, 2021 Category: Pharmaceuticals Source Type: news

Novel Gene Therapy Promising for Rare Neurologic Disorder Novel Gene Therapy Promising for Rare Neurologic Disorder
Targeting the putamen with a novel gene therapy may lead to sustained improvement in motor and nonmotor functions in children with the ultra-rare genetic disorder AADC deficiency.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - August 26, 2021 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Geert Vanden Bossche: Vaccinating people in the middle of a pandemic promotes spread of deadly "variants"
(Natural News) Expert virologist Dr. Geert Vanden Bossche is once again sounding the alarm about the public health emergency that is the government’s mass vaccination campaign right in the middle of a “pandemic.” While it may not be politically correct to say so, Bossche continues to warn that mass injecting people with experimental gene therapy... (Source: NaturalNews.com)
Source: NaturalNews.com - August 17, 2021 Category: Consumer Health News Source Type: news

VTX-801 receives U.S. FDA Fast Track designation for the treatment of Wilson Disease
Vivet Therapeutics ("Vivet"), a clinical-stage biotechnology company, and Pfizer Inc. (NYSE: PFE) announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to VTX-801, Vivet's clinical-stage gene therapy for the treatment of Wilson Disease - a rare, genetic disorder that reduces the ability of the liver and other tissues to regulate copper levels, causing severe hepatic damage, neurological symptoms, and potentially death. (Source: World Pharma News)
Source: World Pharma News - August 13, 2021 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Participant ’s Diagnosis Halts Gene Therapy Clinical Trial
The FDA pauses the research program on a lentivirus-based treatment for a rare neurological condition after a patient developed a bone marrow disorder that could presage leukemia. (Source: The Scientist)
Source: The Scientist - August 12, 2021 Category: Science Tags: News & Opinion Source Type: news

Catalent Appoints Harold Jenkins as General Manager of its Clinical...
Catalent, the leading global provider of advanced delivery technologies, development, manufacturing and clinical supply solutions for drugs, biologics, cell and gene therapies, and consumer health...(PRWeb August 12, 2021)Read the full story at https://www.prweb.com/releases/catalent_appoints_harold_jenkins_as_general_manager_of_its_clinical_supply_facility_in_philadelphia/prweb18127005.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 12, 2021 Category: Pharmaceuticals Source Type: news

Catalent to Supply Edenbridge Pharmaceuticals with a Fast-Dissolve...
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today...(PRWeb August 10, 2021)Read the full story at https://www.prweb.com/releases/catalent_to_supply_edenbridge_pharmaceuticals_with_a_fast_dissolve_zydis_formulation_of_glycopyrrolate_intended_as_adjunctive_therapy_for_patients_with_peptic_ulcer/prweb18120913.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 10, 2021 Category: Pharmaceuticals Source Type: news

Governments hold citizens HOSTAGE, demand vaccine QUOTAS before restoring "freedom"
(Natural News) Around the world, rogue governments are now declaring their own citizens to be hostages under medical tyranny, promising that freedom will be restored if they meet vaccine quotas that require mass injections with experimental gene therapy drugs. (They’re not merely “vaccines.”) In other words, you now have to “earn” your “freedom” from government... (Source: NaturalNews.com)
Source: NaturalNews.com - August 6, 2021 Category: Consumer Health News Source Type: news